The Lancet Regional Health. Americas (Jul 2024)

Epidemiology of systemic sclerosis in Quebec, Canada: a population-based studyResearch in context

  • Anastasiya Muntyanu,
  • Katherine Aw,
  • Mohammed Kaouache,
  • Elham Rahme,
  • Mohamed Osman,
  • Murray Baron,
  • Stephanie Ghazal,
  • Elena Netchiporouk

Journal volume & issue
Vol. 35
p. 100790

Abstract

Read online

Summary: Background: Systemic sclerosis (SSc) is a systemic life-threatening autoimmune rheumatic disease. We aimed to assess the incidence, prevalence, mortality and spatiotemporal trends of SSc in Quebec, Canada with stratification by sex and age. Methods: SSc cases were identified from Quebec populational databases from 1989 to 2019. Negative Binomial (NB) Generalized Linear Models were used for age-standardized incidence rates (ASIR) analyses and NB random walk for prevalence and mortality. A Poisson Besag-York-Mollié regression model was used for spatial analysis. Findings: 8180 incident SSc cases were identified between 1996 and 2019 with an average age of 57.3 ± 16.3 years. The overall ASIR was 4.14/100,000 person-years (95%, Confidence Interval (CI) 4.05–4.24) with a 4:1 female predominance. ASIR increased steadily over time with an Average Annual Percent Change (AAPC) of 3.94% (95% CI 3.49–4.38). While the highest incidence rates were in those aged 60–79 years old among females and >80 years old among males, the highest AAPC (∼10%) was seen in children. Standarized incidence ratios varied geographically between 0.52 to 1.64. The average prevalence was 28.96/100,000 persons (95% CI 28.72–29.20). The Standardized Mortality Ratio (SMR) decreased from 4.18 (95% CI 3.64–4.76) in 1996 to 2.69 (95% CI 2.42–2.98) in 2019. Females had a greater SMR until 2007 and males thereafter. The highest SMR was in children and young adults [31.2 (95% CI 8.39–79.82) in the 0–19-year age group]. Interpretation: We showed an increasing trend in SSc incidence and prevalence and a decline in SMR over a 25-year period in Quebec. An uneven geographic distribution of SSc incidence was demonstrated. Funding: National Scleroderma Foundation, Canadian Dermatology Foundation/Canadian Institutes of Health Research.

Keywords